|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Stakeholder Opinions: Endometriosis
Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of
Stakeholder Insight: Parkinsons Disease
Parkinson’s disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the s
Stakeholder Insight: Osteoporosis
This report is based on a survey of 180 physicians across the seven major markets covering key issues in osteopenia and osteoporosis; including epidemiology, presentation, diagnosis and treatment trends, prescribing influences, and brand assessments.<
Stakeholder Insight: Acute Stroke - TPA spurs infrastructure
Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is res
Stakeholder Insight: Acute Coronary Syndromes
The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patie
Stakeholder Insight: Prostate Cancer
As a result of market dominance by agents such as leuprolide, and AstraZeneca’s Zoladex (goserelin) and Casodex (bicalutamide), there is little space in the antihormonal therapies market for new competition unless significant clinical superiorit
Stakeholder Insight: Diabetes
Type 2 diabetes is an emerging epidemic driven by the escalating prevalence of obesity and by an ageing population. Diagnosis rates will continue to increase as improved awareness raises the public profile of the disease. Despite several established c
Stakeholder Insight: Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn’s disease and ulc
Stakeholder Insight: Renal Cancer
Key issues in the renal cancer market including forecast epidemiology data, current diagnosis and treatment patterns, treatment outcomes and prescribing influences in the 7 major pharmaceutical markets. Particular focus on renal-cell carcinoma (RCC).<
Stakeholder Insight: Orthopedic Postoperative Pain
Postoperative pain can be caused by many different surgical procedures, each involving a variety of complications and physician specialties. Pain is a subjective experience for patients and it would seem that prescribing is driven by physicians` subje
Stakeholder Insight: COPD - Another Reason to Quit
COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands
Stakeholder Insight: Hepatitis in China - Liver Let Die?
Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV vaccination, together with HBV and HCV screening have helped to reduce transmission, but continued t
Stakeholder Insight: Hypertension - Multiple Layers
Hypertension is a deadly disease and an important global public health challenge. Datamonitor estimates that there are currently 192m people with hypertension in the seven major markets, and this number is set to rise to 212m by 2015. Yet, a significa
Stakeholder Insight: Asthma - Combination Therapy
According to the US National Heart, Lung, and Blood Institute and the European Respiratory Society, the annual cost of asthma is estimated to be $16.1 billion in the US and $16.3 billion in the EU. Over 41.5 million people, equivalent to the population
Stakeholder Insight: Dyslipidemia - Statins Dominate...
Datamonitor estimates that there are 267m people in the seven major markets with total cholesterol >200mg/dL which is set to rise to 287m in 2015. Despite this vast patient potential, low diagnosis rates limit the market size, and with the launch of g
Stakeholder Insight: Cognitive Impairment in Schizoaffective...
Cognitive impairment is regarded as a core deficit of schizophrenia; the primary unmet need is the availability of an effective drug for the treatment of cognitive impairment in schizophrenia (CIS). However manufacturers will need to carefully conside
Stakeholder Insight: HIV - A way of life
HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently th
Stakeholder Insight: Heart Failure - Pumping Up Therapy
During the past two decades, heart failure has emerged as a major chronic disease among the elderly population in the major pharmaceutical markets. The leading cause of hospitalization among patients over the age of 65 in Western markets, heart failur
Stakeholder Insight: Prostate Cancer - Waiting for Innovations
The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of p
Stakeholder Insight: Breast Cancer - Changing Treatment...
Anthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer. In recent days, however, agents such as Sanofi-Aventis`s Taxotere and AstraZeneca`s Arimidex have been gaining prominence. This report exami
Stakeholder Insight: Acute Stroke - Symptom Awareness
Stroke is one of the top three causes of death and incidence is expected to increase in the next ten years. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general aware
Stakeholder Insight: HIV Related Neuropathic Pain
Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market. Not only does HIVNP offer a well-served pati
Stakeholder Insight: Fibromyalgia - Substantial Growth
Fibromyalgia is a relatively common chronic pain syndrome, affecting around 2% of the population. This little understood market suffers from high unmet need both at the level of drug research and current clinical practice. Several leading industry pla
Stakeholder Insight: Neuropathic Low Back Pain
Despite millions of patients worldwide, not one neuropathic pain drug company is prioritizing the neuropathic low back pain (NLBP) market. The problem is simply that this patient group is difficult to define in clinical practice. Once diagnosis is mad
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. Datamonitor`s Local and Locally Advanced Prostate Cancer
Stakeholder Insight: Metabolic Syndrome - A Ticking Time Bomb
Datamonitor estimates that approximately 115 million individuals suffer from metabolic syndrome in the seven major markets. This patient population is set to grow rapidly in response to the rising obesity and diabetes epidemics. Research conducted by D
|
